Esperion Therapeutics (ESPR): Pivotal Bempedoic Acid Program Fully Underway - Needham

Needham & Company analyst, Chad Messer, reiterated his Buy rating on shares of Esperion Therapeutics (NASDAQ: ESPR) after the company announced the initiation of three Phase III LDLC lowering efficacy trials in addition to the initiation of the cardiovascular outcomes trials (CVOT) for bempedoic acid. Data from the three efficacy trials is expected mid-2018 with CVOT data in 2020-2021.

The analyst conservatively values shares based on a post-CVOT 2022 approval in the U.S. An earlier LDL-based approval in the U.S. would represent significant upside for his estimates which could play our if the PCSK9 CVOTs read out is positive in 1H17.

No change to the price target of $25.

For an analyst ratings summary and ratings history on Esperion Therapeutics click here. For more ratings news on Esperion Therapeutics click here.

Shares of Esperion Therapeutics closed at $13.84 yesterday.

You May Also Be Interested In

• MaxLinear (MXL) PT Raised to $100 at Needham
• Canadian National Railway (CNI) PT Raised to $139 at Evercore ISI
• Robinhood Markets (HOOD) PT Raised to $123 at Needham